8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)-
Parkinsonian Disorder
Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Alseres Pharmaceuticals, Inc
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00724906CT.gov Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinsonian Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)- (this asset) | Alseres Pharmaceuticals, Inc | P3 | B · 60 |
| .Beta.-Cit | Institute for Neurodegenerative Disorders | P2 | BBB |
| Ioflupane | GE Healthcare | P3 | BB |
| Levodopa | Institute for Neurodegenerative Disorders | P2 | B |
| Pramipexole | Institute for Neurodegenerative Disorders | P2 | B |
| Blood, Whole | University Hospital, Bordeaux | Unk | D |
| 2-Bromo-?-ergocryptine | Institute of Liver and Biliary Sciences, India | N/A | D |
| Carbidopa | Institute for Neurodegenerative Disorders | N/A | D |
| Rifaximin | Institute of Liver and Biliary Sciences, India | N/A | D |
+2 more in the Parkinsonian Disorder cohort
Other indications for 8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Movement Disorder | — | P2 | CCC · 53 |
| Parkinson Disease | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(4-FLUOROPHENYL)-8-((2E)-3-IODO-2-PROPEN-1-YL)-, METHYL ESTER, (1R,2S,3S,5S)- in Parkinsonian Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/8-azabicyclo321octane-2-carboxylic-acid-3-4-fluorophenyl-8-2e-3-iodo-2-propen-1-yl-methyl-ester-1r2s3s5s-parkinsonian-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →